Effects of Atorvastatin on Myonecrosis

NCT00344019

Last updated date
Study Location
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Coronary Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must be aged 18 or over.

- Patients must provide written informed consent.

- Patients are presenting with unstable angina (defined as new onset chest pain, accelerating chest pain, chest pain at rest and ST-segment depression on the electrocardiogram [EKG])

- Patients undergoing successful coronary stent implantation of the (presumed) culprit lesion (defined as < 50% residual stenosis).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any patient who is unable to give written informed consent.


- Any condition which, in the investigator's opinion, would interfere with optimal
participation in the study or produce a significant risk to the patient.


- Patients presenting with an ST-elevation myocardial infarction (MI).


- Patients with elevated troponin, CK, or CK-MB (above the upper limit of normal).


- Patients already on high-dose statin therapy (defined as any statin equivalent to
atorvastatin ≥ 40 mg).


- Patients who took any statin agent within 24 hours of presentation to the cardiac
catheterization laboratory.


- Patients with active hepatic disease or myositis, in whom statin therapy is
contraindicated.


- Patients with hypersensitivity to atorvastatin.


- Patients with procedural complications, including unsuccessful percutaneous
transluminal coronary angioplasty (PTCA)/stenting, major side-branch occlusion,
flow-limiting dissections at the completion of the procedure, emergent coronary artery
bypass surgery, peri-procedural thrombus formation with distal embolization, stent
thrombosis within the first 24 hours, repeat emergent PCI within 24 hours, and death
within 24 hours.


- Cardiogenic shock.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Coronary DiseaseEffects of Atorvastatin on Myonecrosis
NCT00344019
  1. Boston, Massachusetts
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Effects of Atorvastatin on Myonecrosis
Official Title  ICMJE Effects of Single-Dose Atorvastatin on Peri-Procedural Myonecrosis During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes - The NO-MI Study
Brief Summary This study is designed as a prospective, randomized, placebo-controlled, double-blind analysis of atorvastatin 80 mg versus placebo administered on average 4 hours prior to percutaneous coronary intervention [PCI] (at least 2 hours) in patients presenting with unstable angina. Only patients with negative cardiac biomarkers, measured on 2 separate occasions a few hours apart will be eligible for inclusion. Furthermore, patients already on high-dose statin therapy; patients taking any statin within 24 hours prior to the PCI; and patients with contraindications to statins will be excluded from the study. The primary endpoint is a quantitative troponin level at 18-24 hours after PCI. At an enrollment of a total of 150 patients (75 per group), the study is powered to detect a 30% difference in troponin level. Secondary endpoints include elevation of creatine kinase (CK) and CK-MB above the upper limit of normal, change in C-reactive protein (CRP) levels from baseline and thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade. All patients will be started on statin therapy the day after the procedure, as deemed appropriate by their treating physicians.
Detailed Description

STUDY OBJECTIVES:

  1. The primary endpoint of the study is to evaluate the effects of a single high dose of atorvastatin versus placebo on peri-procedural myonecrosis, as measured by troponin T (TnT), during percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndromes (ACS).
  2. Secondary endpoints include the measurements of other biomarkers of myocyte injury (CK, CK-MB) and inflammation (CRP).
  3. Other secondary endpoints include the relative angiographic efficacy of atorvastatin versus placebo on the post PCI growth of tissue level perfusion circumference and the post PCI growth of tissue level perfusion brightness using digital subtraction angiography.

METHODS:

I. Selection and Number of Patients

The study subjects are to be selected from those patients presenting to the BIDMC for cardiac catheterization. Eligible patients will be identified in the cardiac catheterization holding area prior to their procedure. After obtaining informed consent, patients will be randomized to a single dose of atorvastatin or placebo, which will be administered in the holding area about 4 hours prior to the procedure. There will be a total of 150 subjects enrolled in the study. There are a total of 2500 PCIs performed at the BIDMC per year, a third of which are for ACS. We anticipate that 30-40% of patients with ACS will be eligible for study participation.

II. Informed Consent

Informed consent will be obtained from all individuals prior to enrolment in the study according to local Internal Review Board guidelines.

III. Pretreatment Data Collection

Baseline clinical data will be recorded at enrolment and will include: Subject's age, sex, weight and height, diabetes, hypertension, smoking status, hypercholesterolemia (including cholesterol levels if available), the presence of coronary or peripheral artery disease and prior history of PCI or coronary artery bypass surgery. Further, all current medications will be recorded. A detailed angina history will be collected from the patient and the medical record looking for evidence of unstable angina as defined by Braunwald.

IV. Medications

A. Study Medication

Patients will be randomly assigned to atorvastatin 80 mg po or placebo in a double-blind fashion. The study medication will be administered immediately after informed consent is obtained and the patient is randomized to a treatment group in the cardiac catheterization holding area. Given the typical waiting time between first presentation in the holding area and PCI in a non-emergent case, it is estimated that the study medication will be administered 4 hours prior to the procedure (minimal time of 2 hours). All patients will receive a single dose of study medication prior to the procedure. After the completion of the procedure, all statin therapy will be withheld until the next day. Eligible patients can then receive statin therapy according to the treating physicians' preferences. All potential adverse reactions to the study medication will be recorded.

B. Concomitant Therapy

Aspirin (325 mg/day) will be administered prior to intervention and during follow-up. Clopidogrel (300 mg or 600 mg bolus followed by 75 mg/day) will be administered post-stent deployment. It is expected that the majority of patients will receive a glycoprotein IIb/IIIa inhibitor during the procedure and for 18 hours thereafter.

V. Procedures

A. Laboratory Tests

At baseline, levels of troponin, CK and CK-MB will be obtained at the time of presentation and immediately prior to PCI. Patients with any of these serum markers above the upper limit of normal will be excluded from the study. Post-procedural enzymes will be obtained 6-8 hours after the procedure and the next morning (18-24 hours after the procedure). Patients with elevated enzymes may undergo further sampling to determine the peak enzyme rise. The peak troponin level obtained from any post-procedural blood draw will be used as the primary endpoint. Furthermore, baseline CRP levels will be obtained prior to PCI and on the next day.

B. Digital Subtraction Angiography

To quantitate the kinetics of dye entry into the myocardium, digital subtraction angiography can be used. Digital subtraction angiography will be performed at end diastole by aligning cineframe images before dye filled the myocardium with the frame in which dye first reached its peak brightness. The spine, ribs, diaphragm and the epicardial artery are then subtracted. A representative region of the myocardium is sampled that is free of overlap by epicardial arterial branches to determine the increase in the gray scale brightness of the myocardium. The circumference of the myocardial blush is measured using a handheld planimeter (Fowler, Inc). The frame count ÷ number of frames per second is used to measure the time elapsed during angiography to quantitate the rate of rise in the growth (cm/sec) and brightness (gray/sec) of myocardial blush. Blush will also be assessed visually using the TIMI myocardial perfusion grade.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
randomized trial of 80 mg atorvastatin vs. placebo pre PCI
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Coronary Disease
Intervention  ICMJE
  • Drug: Placebo Oral Tablet
    placebo pre-PCI for ACS
  • Drug: Atorvastatin 80mg
    atorvastatin 80 mg pre-angio/PCI
    Other Name: lipitor
  • Other: Screening
    Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
Study Arms  ICMJE
  • Active Comparator: atorvastatin 80 mg
    80 mg atorvastatin on average of 2-4 hours pre angio/PCI for ACS
    Interventions:
    • Drug: Atorvastatin 80mg
    • Other: Screening
  • Placebo Comparator: placebo oral tablet
    placebo on average of 2-4 hours pre angio/PCI for ACS
    Interventions:
    • Drug: Placebo Oral Tablet
    • Other: Screening
  • No Intervention: Screening
    Patients signed consent if willing to participate. Patients will continue onto randomization if appropriate per inc/exc (i.e. stent placement) otherwise screen fail
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: December 1, 2017)
97
Original Enrollment  ICMJE
 (submitted: June 22, 2006)
150
Actual Study Completion Date  ICMJE January 2009
Actual Primary Completion Date October 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must be aged 18 or over.
  • Patients must provide written informed consent.
  • Patients are presenting with unstable angina (defined as new onset chest pain, accelerating chest pain, chest pain at rest and ST-segment depression on the electrocardiogram [EKG])
  • Patients undergoing successful coronary stent implantation of the (presumed) culprit lesion (defined as < 50% residual stenosis).

Exclusion Criteria:

  • Any patient who is unable to give written informed consent.
  • Any condition which, in the investigator's opinion, would interfere with optimal participation in the study or produce a significant risk to the patient.
  • Patients presenting with an ST-elevation myocardial infarction (MI).
  • Patients with elevated troponin, CK, or CK-MB (above the upper limit of normal).
  • Patients already on high-dose statin therapy (defined as any statin equivalent to atorvastatin ? 40 mg).
  • Patients who took any statin agent within 24 hours of presentation to the cardiac catheterization laboratory.
  • Patients with active hepatic disease or myositis, in whom statin therapy is contraindicated.
  • Patients with hypersensitivity to atorvastatin.
  • Patients with procedural complications, including unsuccessful percutaneous transluminal coronary angioplasty (PTCA)/stenting, major side-branch occlusion, flow-limiting dissections at the completion of the procedure, emergent coronary artery bypass surgery, peri-procedural thrombus formation with distal embolization, stent thrombosis within the first 24 hours, repeat emergent PCI within 24 hours, and death within 24 hours.
  • Cardiogenic shock.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00344019
Other Study ID Numbers  ICMJE 2006P000035
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:no plans to share data
Responsible Party Beth Israel Deaconess Medical Center
Study Sponsor  ICMJE Beth Israel Deaconess Medical Center
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Joseph Carrozza, Jr, MDBeth Israel Deaconess Medical Center
PRS Account Beth Israel Deaconess Medical Center
Verification Date December 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP